New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - tebuconazole; prothioconazole - emulsifiable concentrate - tebuconazole 80 g/litre; prothioconazole 160 g/litre - fungicide - fungicide

New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - isoflucypram - emulsifiable concentrate (ec) - isoflucypram 50 g/litre - fungicide - fungicide

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mylan healthcare sdn. bhd. - atorvastatin calcium -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mylan healthcare sdn. bhd. - atorvastatin calcium -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mylan healthcare sdn. bhd. - atorvastatin calcium -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

mylan healthcare sdn. bhd. - atorvastatin calcium -

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - umeclidinium as bromide - powder for inhalation - umeclidinium as bromide 55 mcg - umeclidinium bromide - incruse is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).

Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - umeclidinium as bromide; vilanterol as trifenatate - powder for inhalation - vilanterol as trifenatate 22 mcg; umeclidinium as bromide 55 mcg - vilanterol and umeclidinium bromide - anoro is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (copd).anoro ellipta is not indicated for the relief of acute bronchospasm or for the treatment of asthma.

Israel - English - Ministry of Health

novartis israel ltd - dabrafenib as mesilate - hard capsule - dabrafenib as mesilate 50 mg - dabrafenib - dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.non-small cell lung cancer (nsclc) :dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.adjuvant treatment of melanoma :dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with braf v600 mutation, following complete resection.braf v600e mutation-positive locally advanced or metastatic anaplastic thyroid cancertafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment optionsbraf v600e mutation-positive unresectable or metastatic solid tumorstafinlar is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. limitations of use: dabrafenib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibition. dabrafenib is indicated, in combination with trametinib, for the treatment of pediatric patients 6 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy

Israel - English - Ministry of Health

novartis israel ltd - dabrafenib as mesilate - hard capsule - dabrafenib as mesilate 50 mg - dabrafenib - dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.non-small cell lung cancer (nsclc) :dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.adjuvant treatment of melanoma : dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with braf v600 mutation, following complete resection.braf v600e mutation-positive locally advanced or metastatic anaplastic thyroid cancertafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment options